Review

Causes and Characteristics of Diabetic Cardiomyopathy

Jianxun Wang¹, Ye Song², Qianwen Wang³, Patricia M. Kralik², Paul N. Epstein²

Keywords: diabetes, cardiomyopathy, coronary artery disease, obesity, hyperglycemia, insulin, angiotensin

Abstract

Type 1 and type 2 diabetic patients are at increased risk of cardiomyopathy and heart failure is a major cause of death for these patients. Cardiomyopathy in diabetes is associated with a cluster of features including decreased diastolic compliance, interstitial fibrosis and myocyte hypertrophy. The mechanisms leading to diabetic cardiomyopathy remain uncertain. Diabetes is associated with most known risk factors for cardiac failure seen in the overall population, including obesity, dyslipidemia, thrombosis, infarction, hypertension, activation of multiple hormone and cytokine systems, autonomic neuropathy, endothelial dysfunction and coronary artery disease. In light of these common contributing pathologies it remains uncertain whether diabetic cardiomyopathy is a distinct disease. It is also uncertain which factors are most important to the overall incidence of heart failure in diabetic patients. This review focuses on factors that can have direct effects on diabetic cardiomyocytes: hyperglycemia, altered fuel use, and changes in the activity of insulin and angiotensin. Particular attention is given to the changes these factors can have on cardiac mitochondria and the role of reactive oxygen species in mediating injury to cardiomyocytes.

Fulltext: HTML , PDF (302KB)

This article has been cited by other articles:

	Emerging role of epigenetics and miRNA in diabetic cardiomyopathy Asrih M, Steffens S Cardiovasc Pathol 2012. Epub
	Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes Maalouf RM, Eid AA, Gorin YC, Block K, Escobar GP, Bailey S, Abboud HE Am J Physiol Cell Physiol 2012. 302(3):C597-C604
	Particulate matter exposure exacerbates high glucose-induced cardiomyocyte dysfunction through ROS generation Zuo L, Youtz DJ, Wold LE PLoS One 2011. 6(8):e23116
	Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats Dong SF, Hong Y, Liu M, Hao YZ, Yu HS, Liu Y, Sun JN Eur J Pharmacol 2011. 660(2-3):368-374
	Potential role of nuclear factor kappaB in diabetic cardiomyopathy Lorenzo O, Picatoste B, Ares-Carrasco S, Ramirez E, Egido J, Tunon J Mediators Inflamm 2011. 2011:652097
	Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease Azhar S Future Cardiol 2010. 6(5):657-691
	Maternal obesity induces fibrosis in fetal myocardium of sheep Huang Y, Yan X, Zhao JX, Zhu MJ, McCormick RJ, Ford SP, Nathanielsz PW, Ren J, Du M Am J Physiol Endocrinol Metab 2010. 299(6):E968-E975
	The absence of pathological myofibre disarray in the diabetic heart: is it a paradox? McLachlan CS, Lasker S, Keramat SM, Wang L, Jelinek H Acta Cardiol 2009. 64(2):267-268
	Shotgun Lipidomics of Neutral Lipids as an Enabling Technology for Elucidation of Lipid-Related Diseases Gross RW, Han X Am J Physiol Endocrinol Metab 2009. 297(2):E297-E303
	Animal models of diabetes mellitus: relevance to vascular complications Thompson CS Curr Pharm Des 2008. 14(4):309-324
	Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats Ceylan-Isik A, Hünkar T, Asan E, Kaymaz F, Ari N, Söylemezoglu T, Renda N, Soncul H, Bali M, Karasu C; The ADIC Study Group J Pharm Pharmacol 2007. 59(12):1629-1641
	Diabetic Cardiomyopathy in OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo and In Vitro Contractility Song Y, Du Y, Prabhu SD, Epstein PN Rev Diabet Stud 2007. 4(3):159-168